Not your typical investor.
I have lived the founder’s life: the raise, the listing, the winddown and the sale. I help founders find the right type of money at the right inflection point, and where it fits, Kash Ventures invests alongside them.
What I back
- Cheque size
- $50K to $500K
- Stage
- Pre-seed to Series A
- Where I go deepest
- Health services, preventive care, healthcare technology and B2B software. Open to any industry with the right founder.
- Geography
- Canada and the United States, including cross-border builds
- The founder
- Coachable, builds trust quickly, with traction or a clear wall to break through
- How I show up
- A written operating mandate, and a board or observer seat where the stake justifies it
The right type of money
Most founders raise the wrong money at the wrong time. Every stage of capital is a different buyer wanting a different thing.
Friends and family buy you. Angels buy the bet. Venture buys the outcome. Institutions buy predictability. Strategic investors buy fit. Lenders buy certainty, and they will want it back on their timeline, not yours.
I have raised from every one of them, more than $60M from friends and family to NASDAQ, and I have watched the music stop. My job is to help you know which room you are in before you walk into it.
What I don’t do
- Passive cheques that wait for an update email.
- Advisor titles with no scope and no time attached.
- Deals where the founder and I want different endings.
Current and recent roles
Roles shown, not terms.
Momenta Analytics
Chief Strategy OfficerThe context layer for AI, built from the SQL a company already runs. Strategy, partners and capital.Angel One Investor Network
Member, angel investorBurlington-based network of accredited investors backing early-stage companies across Southern Ontario.CloudCure
Advisor and investorMetabolic health and telehealth across provinces. Capital strategy and the structure behind the expansion.MORO
AdvisorA care companion for non-speaking individuals. Founder clarity and the first investor story.A US clinical research company
Board memberThrough its sale to a private-equity-backed strategic buyer in 2026.Raising, or about to?
Let’s make sure you are pitching the right thing to the right room, and talk about whether Kash Ventures should be in it.